BidaskClub upgraded shares of Esperion Therapeutics (NASDAQ:ESPR) from a hold rating to a buy rating in a report released on Wednesday morning.
Several other brokerages also recently weighed in on ESPR. Zacks Investment Research downgraded Esperion Therapeutics from a hold rating to a sell rating in a report on Tuesday, July 10th. Northland Securities cut Esperion Therapeutics from an outperform rating to a market perform rating in a research report on Wednesday, July 11th. Cowen set a $82.00 price objective on Esperion Therapeutics and gave the stock a buy rating in a research report on Friday, October 26th. ValuEngine upgraded Esperion Therapeutics from a buy rating to a strong-buy rating in a research report on Thursday, November 1st. Finally, Stifel Nicolaus initiated coverage on Esperion Therapeutics in a research report on Friday, September 14th. They issued a buy rating and a $89.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. The company currently has a consensus rating of Buy and an average price target of $75.96.
Shares of ESPR stock traded down $3.97 during trading hours on Wednesday, hitting $54.49. The stock had a trading volume of 933,235 shares, compared to its average volume of 1,022,921. The company has a market capitalization of $1.58 billion, a P/E ratio of -7.81 and a beta of 2.20. Esperion Therapeutics has a twelve month low of $33.06 and a twelve month high of $82.68.
In other Esperion Therapeutics news, Director Roger S. Newton sold 2,827 shares of the firm’s stock in a transaction dated Friday, November 2nd. The stock was sold at an average price of $50.07, for a total value of $141,547.89. Following the sale, the director now directly owns 573,953 shares of the company’s stock, valued at approximately $28,737,826.71. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Boxer Capital, Llc sold 100,000 shares of the firm’s stock in a transaction dated Monday, November 5th. The stock was sold at an average price of $56.38, for a total value of $5,638,000.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 177,327 shares of company stock worth $9,732,065. 32.50% of the stock is owned by corporate insiders.
A number of large investors have recently modified their holdings of the business. BTG Pactual Global Asset Management Ltd boosted its stake in Esperion Therapeutics by 20.2% in the 2nd quarter. BTG Pactual Global Asset Management Ltd now owns 8,719 shares of the biopharmaceutical company’s stock worth $342,000 after buying an additional 1,465 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its stake in Esperion Therapeutics by 40.6% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after buying an additional 2,224 shares during the last quarter. Creative Planning boosted its stake in Esperion Therapeutics by 42.0% in the 3rd quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock worth $336,000 after buying an additional 2,236 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Esperion Therapeutics by 3.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 71,095 shares of the biopharmaceutical company’s stock worth $3,155,000 after buying an additional 2,348 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in Esperion Therapeutics by 53.9% in the 1st quarter. Legal & General Group Plc now owns 6,751 shares of the biopharmaceutical company’s stock worth $488,000 after buying an additional 2,363 shares during the last quarter.
Esperion Therapeutics Company Profile
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Featured Story: What is the Book Value of a Share?
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.